Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 3/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25477793 | 0.89 | ALDH1A1 (0.40) | TP53SMN1; SMN2HRH3SCN1ASCN2A | |
| SCHEMBL24672987 | 0.87 | KDM4E (0.42) | TP53SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23696532 | 0.87 | KDM4E (0.42) | TP53SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL26406493 | 0.87 | KDM4E (0.36) | TP53SMN1; SMN2SCN1ASCN2ASCN3A | |
| SCHEMBL24673349 | 0.87 | TP53 (0.34) | PRMT6TP53SMN1; SMN2SCN1ASCN2A | |
| SCHEMBL25886631 | 0.86 | CARM1 (0.33) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL23559986 | 0.86 | HTT (0.34) | TP53SMN1; SMN2SCN1ASCN2ASCN3A | |
| SCHEMBL21106209 | 0.86 | TP53 (0.33) | TP53SMN1; SMN2SCN1ASCN2ASCN3A | |
| SCHEMBL23696051 | 0.86 | SLC2A1 (0.35) | TP53SMN1; SMN2HRH3 | |
| SCHEMBL22837636 | 0.84 | SLC2A1 (0.34) | TP53SMN1; SMN2HRH3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2021231778-A1 | CORONAVIRUS PROTEASE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CARM1 824/4885PRMT6 1616/4885PRMT8 1981/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CARM1 824/4885PRMT6 1616/4885PRMT8 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.